ODT stock information

Sector:

Healthcare

Description:

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

Odonate Therapeutics, Inc. website

Current Price

$1.12

RSI

35.57

Market Capitalization:

118.6M

Beta:

0.401

Volume:

83,299

Analyst Target Price:

$ 4

Economiic Fair Price:

Report DateJuly 27, 2021

QuarterQ2

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Profit MarginN/A

Revenue Per Share TTM0

Return On Equity TTM-1.247

2020 Free Cash Flow

$ -113.6M

-17.31 %

2019 Free Cash Flow

$ -96.8M

-40.29 %

2018 Free Cash Flow

$ -69M

-165.99 %

2017 Free Cash Flow

$ -25.9M

-1396.88 %

2016 Free Cash Flow

$ -1.7M

-950.30 %

2015 Free Cash Flow

$ -165K

Odonate Therapeutics, Inc.(ODT)